On Flat Q3 Sales, Combimatrix Continues to Explore Strategies | GenomeWeb

NEW YORK (GenomeWeb News) – CombiMatrix reported after the close of the market on Wednesday that its third-quarter revenues slipped around 4 percent year over year, with the decline coming mainly from soft government contracts and product sales.

CombiMatrix brought in total revenues of $970,000 for the three-month period ended Sept. 30, compared to $1 million in the year-ago period.

Revenues for the Mukilteo, Wash.-based company from government contracts fell to $133,000 from $343,000, while revenues from products sales rose to $250,000 from $158,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.